Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NOTCH2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NOTCH2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NOTCH2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NOTCH2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NOTCH2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NOTCH2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00725768 | Thyroid | ATC | liver morphogenesis | 14/6293 | 23/18723 | 6.70e-03 | 2.67e-02 | 14 |
GO:00305095 | Thyroid | ATC | BMP signaling pathway | 66/6293 | 152/18723 | 7.23e-03 | 2.85e-02 | 66 |
GO:0050678110 | Thyroid | ATC | regulation of epithelial cell proliferation | 151/6293 | 381/18723 | 7.47e-03 | 2.92e-02 | 151 |
GO:00303262 | Thyroid | ATC | embryonic limb morphogenesis | 52/6293 | 116/18723 | 7.67e-03 | 3.00e-02 | 52 |
GO:00351132 | Thyroid | ATC | embryonic appendage morphogenesis | 52/6293 | 116/18723 | 7.67e-03 | 3.00e-02 | 52 |
GO:006067413 | Thyroid | ATC | placenta blood vessel development | 17/6293 | 30/18723 | 7.88e-03 | 3.06e-02 | 17 |
GO:00901001 | Thyroid | ATC | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 51/6293 | 114/18723 | 8.62e-03 | 3.28e-02 | 51 |
GO:0002573110 | Thyroid | ATC | myeloid leukocyte differentiation | 86/6293 | 208/18723 | 1.15e-02 | 4.11e-02 | 86 |
GO:00468491 | Thyroid | ATC | bone remodeling | 41/6293 | 90/18723 | 1.21e-02 | 4.30e-02 | 41 |
GO:00725746 | Thyroid | ATC | hepatocyte proliferation | 13/6293 | 22/18723 | 1.25e-02 | 4.38e-02 | 13 |
GO:00725756 | Thyroid | ATC | epithelial cell proliferation involved in liver morphogenesis | 13/6293 | 22/18723 | 1.25e-02 | 4.38e-02 | 13 |
GO:00613187 | Thyroid | ATC | renal filtration cell differentiation | 12/6293 | 20/18723 | 1.39e-02 | 4.81e-02 | 12 |
GO:00721127 | Thyroid | ATC | glomerular visceral epithelial cell differentiation | 12/6293 | 20/18723 | 1.39e-02 | 4.81e-02 | 12 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049191 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049194 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049195 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049198 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
hsa049199 | Colorectum | FAP | Thyroid hormone signaling pathway | 41/1404 | 121/8465 | 2.28e-06 | 4.28e-05 | 2.60e-05 | 41 |
hsa0491910 | Colorectum | CRC | Thyroid hormone signaling pathway | 35/1091 | 121/8465 | 2.05e-06 | 6.85e-05 | 4.64e-05 | 35 |
hsa05207 | Colorectum | CRC | Chemical carcinogenesis - receptor activation | 42/1091 | 212/8465 | 2.62e-03 | 1.75e-02 | 1.19e-02 | 42 |
hsa0491911 | Colorectum | CRC | Thyroid hormone signaling pathway | 35/1091 | 121/8465 | 2.05e-06 | 6.85e-05 | 4.64e-05 | 35 |
hsa052071 | Colorectum | CRC | Chemical carcinogenesis - receptor activation | 42/1091 | 212/8465 | 2.62e-03 | 1.75e-02 | 1.19e-02 | 42 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0491928 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa015227 | Esophagus | ESCC | Endocrine resistance | 63/4205 | 98/8465 | 2.38e-03 | 6.58e-03 | 3.37e-03 | 63 |
hsa043306 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
hsa046585 | Esophagus | ESCC | Th1 and Th2 cell differentiation | 58/4205 | 92/8465 | 6.49e-03 | 1.60e-02 | 8.19e-03 | 58 |
hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa04919113 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0152215 | Esophagus | ESCC | Endocrine resistance | 63/4205 | 98/8465 | 2.38e-03 | 6.58e-03 | 3.37e-03 | 63 |
hsa0433013 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
hsa0465812 | Esophagus | ESCC | Th1 and Th2 cell differentiation | 58/4205 | 92/8465 | 6.49e-03 | 1.60e-02 | 8.19e-03 | 58 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NOTCH2 | SNV | Missense_Mutation | | c.4888C>G | p.Arg1630Gly | p.R1630G | Q04721 | protein_coding | deleterious(0.03) | probably_damaging(0.95) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
NOTCH2 | SNV | Missense_Mutation | novel | c.4163N>C | p.Ser1388Thr | p.S1388T | Q04721 | protein_coding | tolerated(1) | benign(0) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
NOTCH2 | SNV | Missense_Mutation | | c.6991G>T | p.Ala2331Ser | p.A2331S | Q04721 | protein_coding | tolerated(0.78) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NOTCH2 | SNV | Missense_Mutation | | c.3044N>C | p.Val1015Ala | p.V1015A | Q04721 | protein_coding | tolerated(0.27) | benign(0.015) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NOTCH2 | SNV | Missense_Mutation | | c.804N>T | p.Arg268Ser | p.R268S | Q04721 | protein_coding | tolerated(0.65) | benign(0.037) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
NOTCH2 | SNV | Missense_Mutation | novel | c.290N>G | p.Thr97Arg | p.T97R | Q04721 | protein_coding | tolerated(0.1) | probably_damaging(0.979) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
NOTCH2 | SNV | Missense_Mutation | rs376783592 | c.1698G>T | p.Leu566Phe | p.L566F | Q04721 | protein_coding | tolerated(0.7) | possibly_damaging(0.77) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NOTCH2 | SNV | Missense_Mutation | | c.4996N>T | p.Val1666Phe | p.V1666F | Q04721 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-B6-A0X0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NOTCH2 | SNV | Missense_Mutation | | c.4812N>T | p.Arg1604Ser | p.R1604S | Q04721 | protein_coding | tolerated(0.57) | benign(0.007) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
NOTCH2 | SNV | Missense_Mutation | novel | c.2864G>A | p.Ser955Asn | p.S955N | Q04721 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | inhibitor | MK0752 | | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | antibody | 252166663 | TAREXTUMAB | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | inhibitor | RO4929097 | RG-4733 | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | inhibitor | PF-03084014 | NIROGACESTAT | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | antibody | REGN421 | | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | | Tarextumab | TAREXTUMAB | |
4853 | NOTCH2 | DRUGGABLE GENOME, CELL SURFACE, CLINICALLY ACTIONABLE | | OMP-59R5 | TAREXTUMAB | |